In The News: School of Integrated Health Sciences

Journal of Athletic Training

Dr. Kara Radzak discusses recent updates in sport-related concussion assessment and rehabilitation with Dr. Abigail Bretzin, Dr. Jaclyn Caccese, and Dr. Justin Karr.

Las Vegas Sun

The occupational therapists in training at UNLV will one day work with people recovering from strokes, injury — and COVID-19.

Las Vegas Sun

Picture of UNLV School of Integrated Health Sciences students working on mobility training practices with infant dolls at the Occupational Therapy lab facility at the Shadow Lane campus.

KSNV-TV: News 3

It’s training that’s been in use for generations.

Yahoo!

Resverlogix Corp., a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly improves cognition and reduces cognitive decline among high-risk patients with cardiovascular disease and diabetes mellitus.

KVVU-TV: Fox 5

UNLV launched new Occupational Therapy program that trains students in a home instead of a classroom or lab.

Men's Journal

Right now you can nab a fantastic deal on the vitamins and supplements you need to get over the proverbial hump.

Men's Journal

When you hit the gym hard, it can be tempting to load up on every shiny tub of mysterious purple powder you can get your hands on in hopes it’ll turn you into vintage Schwarzenegger overnight.

Newswise

Mary Ashley Galan-Gornal grasped the adaptive knife in her right hand, placed the red delicious apple securely in the vise, and sliced off a piece of the fruit.

Nature Medicine

Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.

Alzforum

The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.

PharmiWeb.com

NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced yesterday it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease.